2025年的中国医美市场，在喧嚣中迎来了一个微妙的分水岭。 《每日经济新闻》记者查阅上述消费榜单发现，曾经的"抗衰明星"——超声炮"失速"，玻尿酸则在价格 战的泥潭中稳守"顶流"地位。 对此，有业内分析指出，在合规壁垒趋严与技术迭代提速的背景下，医美市场加速重塑，行业"马太效 应"正在以一种近乎残酷的方式上演，而与此同时，减重与脱发治疗赛道，正成为资本竞逐的一个"新大 陆"。 再生填充材料继续"狂飙" 近日，医美平台美呗发布的"2025年医美平台消费榜单"显示，再生填充材料成为"年度MVP"，2025年销 售额同比增长93.40%，成为连续3年狂飙的"热门选手"。 在整个再生填充材料赛道狂飙的同时，各个品牌2025年销售额的增速却出现分化："臻爱塑菲"以463% 的增长速度排名第一；艾维岚同比增长78.71%，展现出稳扎稳打的特点；"伊妍仕"的市场受到挤压，同 比下降56%。 公开资料显示，"臻爱塑菲"为爱美客旗下产品。 《每日经济新闻》记者了解到，2025年，"臻爱塑菲"销售额增速虽然强劲，但其对爱美客的业绩贡献还 有待验证。财报数据显示，2025年前三季度，爱美客营收和归母净利润均出现超过20%的同比下降 ...

与此同时，曾经的"抗衰明星"超声炮热度锐减过半，玻尿酸则在价格战的泥潭中稳守"顶流"地位。当合 规壁垒与技术迭代加速重塑市场，医美行业的"马太效应"正在以一种近乎残酷的方式上演，而减重与脱 发治疗正成为资本竞逐的下一个新大陆。 再生填充材料狂飙后的断层：463%增长与56%下降的"冰与火" 近日，医美平台美呗发布的《2025医美消费榜》显示，再生填充材料成为"年度MVP"，2025年销售额 同比增长93.40%，成为连续三年狂飙的"热门选手"。 在整个赛道狂奔的同时，各个品牌2025年销售额的增速却出现分化：臻爱塑菲以463%的强势增长排名 第一；艾维岚同比增长78.71%，稳扎稳打；伊妍仕的市场受到挤压，同比下降56%。 每经记者｜陈星 每经编辑｜黄博文 2025年的中国医美市场，在喧嚣中迎来了一个微妙的分水岭。 美呗平台最新数据显示，连续三年狂飙的再生填充材料赛道，在2025年销售额整体增长93.40%的光鲜 之下，还出现了内部断层：爱美客旗下的"臻爱塑菲"以463%的增速强势领跑，而昔日"少女针"王者华 东医药的"伊妍仕"却同比下降56%。 成都高新米兰柏羽医学美容医院皮肤科技术院长、副主任医师陈双瑜表 ...

Core Insights - The strategic partnership between Yuansong Group and Chongshan Biotechnology has led to the launch of the world's first collagen product derived from bovine tendons, named "Jiaoyuan Angel," which received Class III medical device registration approval from the National Medical Products Administration on December 10, 2025 [1][3] - The collagen market in China has reached a scale of 200 billion, with projections to grow to 500 billion by 2030, indicating significant growth potential in the industry [3] Product Advantages - "Jiaoyuan Angel" features a high concentration of medical collagen at 45 mg/ml, ensuring strong support [5] - The product is made from high-purity bovine tendon collagen, which guarantees the integrity of the raw material [5] - Advanced application technology allows for precise subcutaneous implantation, providing deeper support for the skin [5] - The development team overcame several technical challenges, establishing 45 mg/ml as the optimal concentration to balance collagen network formation and safety [5] - The product maintains biological activity and structural integrity through meticulous production processes [5] Market Trends - The introduction of "Jiaoyuan Angel" is expected to shift the focus of collagen applications from immediate filling effects to a trend of nutritional tightening in the industry [7] - Yuansong Group has established a strong presence in the medical aesthetics sector with several successful products, positioning itself as a market leader [7] - Analysts predict that "Jiaoyuan Angel" could capture significant market share quickly, potentially becoming a dark horse in the medical aesthetics market by 2026 [7]

Core Insights - The strategic partnership between Yuansong Group and Chongshan Biotechnology has led to the launch of the world's first collagen product derived from bovine tendons, named "Jiaoyuan Angel," which received regulatory approval on December 10 [1][3] - The collagen market has reached a scale of 200 billion and is projected to grow to 500 billion by 2030, indicating significant growth potential in the industry [3] Product Advantages - "Jiaoyuan Angel" features a high medical collagen concentration of 45 mg/ml, ensuring strong support [5] - The product uses collagen extracted from bovine tendons, ensuring high purity and structural integrity [5] - Advanced application technology allows for precise subcutaneous implantation, providing deeper network support for the skin [5] - The company has addressed industry challenges, establishing 45 mg/ml as the optimal concentration to balance efficacy and safety [5] Market Positioning - The collaboration signifies an upgrade in the synergy between clinical institutions and research enterprises, aiming to redefine the application of collagen in the market [6] - The focus is shifting from "volume enhancement" to "nutritional tightening," which is expected to become the mainstream trend in the collagen market [8] - Yuansong Group has previously launched several successful products in the medical beauty sector, positioning itself as a market leader [8] - "Jiaoyuan Angel" is anticipated to capture significant market share and potentially become a dark horse in the medical beauty market by 2026 due to its technological advantages and promotional capabilities [8]

Core Viewpoint - The acceptance of the registration application for MaiLi Precise by the NMPA marks a significant milestone in the development of high-end hyaluronic acid products by East China Pharmaceutical in the Chinese market [1][4]. Group 1: Product Development and Market Position - MaiLi series is a high-end hyaluronic acid brand under East China Pharmaceutical, consisting of four products, all of which are already launched in Europe [2]. - MaiLi Precise, the product recently accepted for registration, is designed to correct under-eye hollows and has shown good filling performance and safety in clinical trials [4]. - The Chinese hyaluronic acid market is experiencing rapid growth, with a market size increase from 3.1 billion yuan in 2017 to 6.3 billion yuan in 2021, and projected to reach 44.1 billion yuan by 2030, reflecting a compound annual growth rate of 24.2% from 2021 to 2030 [4]. Group 2: Competitive Advantage and Technology - The MaiLi series avoids competition in a saturated market by leveraging its high-end brand positioning and unique OxiFree technology, which preserves long-chain hyaluronic acid and reduces the need for chemical cross-linking agents [5]. - This innovative technology allows for stronger support and a lighter, more flexible effect with less product usage, providing a safer and more effective option for consumers [5]. Group 3: Strategic Expansion and Future Outlook - East China Pharmaceutical is committed to a global operational strategy and has a comprehensive product matrix covering various aesthetic medical fields, including injectables and energy-based devices [6]. - The company is actively expanding its international market presence, with multiple products undergoing registration in regions such as the Middle East and Europe [8]. - A rich pipeline of new products is expected to launch in the coming years, including new high-end hyaluronic acid fillers and a recombinant botulinum toxin, which will further enhance the company's market position [9].

Investment Rating - The report rates the investment outlook for the medical beauty regenerative anti-aging injection industry as "Positive" [5] Core Insights - The regenerative anti-aging injection agents are emerging materials that achieve facial rejuvenation through different mechanisms compared to hyaluronic acid and botulinum toxin [1] - The midstream of the regenerative anti-aging injection industry chain is identified as the segment with the highest added value, supported by regulatory compliance, technological innovation, and market demand [2] - Future trends in the industry include increased demand driven by an aging population, a shift towards non-surgical aesthetic procedures, and advancements in technology and materials that enhance product efficacy [3] Summary by Sections 1. Overview of the Medical Beauty Regenerative Anti-Aging Injection Industry - Medical beauty injection products are categorized into hyaluronic acid, botulinum toxin, and regenerative anti-aging materials, with the latter being newly introduced in the domestic market [11] - Regenerative anti-aging injections include subclasses such as microsphere regeneration, collagen, and PDRN, each with distinct mechanisms and benefits [12][13] 2. Industry Chain Analysis - The midstream segment is characterized by high added value, with companies leveraging compliance, innovation, and production capabilities to establish competitive barriers [2][29] - The upstream involves raw material suppliers, while the downstream focuses on the distribution to end consumers through various channels [26] 3. Regulatory and Policy Environment - The industry is regulated by key agencies including the National Health Commission and the National Medical Products Administration, ensuring compliance across all stages from development to sales [43][46] 4. Market Size and Growth Potential - The market for medical beauty injections in China is projected to grow from 21.2 billion RMB in 2023 to 65.3 billion RMB by 2028, with a CAGR of 25.3% [17] - The regenerative anti-aging segment is expected to see a significant increase, with its market share rising from 3% in 2019 to an estimated 31% by 2028 [20] 5. Investment Recommendations - Companies with a comprehensive industry chain layout and a strong product portfolio, such as Jinbo Biological and East China Pharmaceutical, are highlighted as having strong growth potential and investment value [3]

Core Viewpoint - Oriental Yanmei (Chengdu) Biotechnology Co., Ltd. is pursuing an IPO in Hong Kong despite a high debt-to-asset ratio of 123% and significant financial challenges, including projected losses of nearly 70 million yuan in 2024 and cash reserves of only 33.19 million yuan by the end of 2024 [1][9]. Company Overview - Founded in 2016, Oriental Yanmei focuses on regenerative medical devices and special medical foods, targeting a medical market worth hundreds of billions of yuan [1]. - The company's core product, "Tongyan Needle" XH301, is expected to receive approval in the second half of 2025, while competitors have already established a strong presence in this segment [1][6]. Financial Performance - The company reported revenues of approximately 12.88 million yuan in 2023 and 14.52 million yuan in 2024, primarily from non-core products, with a projected loss of nearly 70 million yuan in 2024 [8][9]. - The gross margin for 2023 and 2024 was 11.4% and 2.6%, respectively, with net losses of 63.5 million yuan and 69.4 million yuan attributed to R&D and operational expenses [9]. Market Potential - The regenerative medical materials injection market has grown from 200 million yuan in 2019 to 2.9 billion yuan in 2023, with a compound annual growth rate (CAGR) of 96.6%, expected to reach 18.5 billion yuan by 2032 [6]. - The special medical food market has also expanded from 2.7 billion yuan in 2019 to 6 billion yuan in 2023, with a CAGR of 17.2%, projected to reach 23.8 billion yuan by 2032 [8]. Management Team - The founder, Zhang Xinming, and key executives have a history of collaboration dating back to their time at Zhi Yuan Pharmaceutical, indicating a strong entrepreneurial bond [2][3]. - Zhang Xinming has extensive experience in the pharmaceutical industry, having worked at various companies including China Resources Sanjiu and Zhi Yuan Pharmaceutical [3][4]. Product Development - Oriental Yanmei has 13 candidate products in the regenerative medical device sector, with XH301 and XH321 currently undergoing registration review [6]. - The company has also developed 7 candidate products in the medical dressing and patch category, with one product already approved [6]. Competitive Landscape - The "Tongyan Needle" market is competitive, with several established players already having products approved, indicating a challenging environment for new entrants [7]. - The average approval cycle for regenerative medical devices is 3 to 5 years, adding to the urgency for Oriental Yanmei to secure funding and expedite its product launch [6][9].

Core Viewpoint - *ST Suwu's stock price fell sharply due to the chairman's investigation for information disclosure violations, raising concerns about the company's future and potential delisting risks [1][3]. Group 1: Company Investigation and Financial Health - On May 14, *ST Suwu announced that its chairman, Qian Qunshan, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected information disclosure violations [1]. - The company has been under investigation since February 27 for similar allegations, and it has not yet received a conclusive opinion from the CSRC [3]. - The accounting firm, Zhongxing Caiguanghua, issued an audit report for 2024 stating it could not express an opinion due to significant overdue receivables totaling 1.062 billion yuan, with 1.027 billion yuan overdue [3]. - The company also reported that 769 million yuan of its funds were occupied by related parties, increasing the risk of delisting [3]. Group 2: Business Strategy and Performance - Since its establishment in 1994, *ST Suwu has diversified into pharmaceuticals, chemicals, and real estate, with a recent focus on the medical aesthetics sector [4]. - The company achieved profitability after two years of losses, with revenues of 2.026 billion yuan in 2022 and 2.240 billion yuan in 2023, and a projected net profit of 55 to 80 million yuan for 2024, largely due to sales of the "Tian Yan Needle" [4]. - The sales revenue from the "Tian Yan Needle" reached 195 million yuan, with a gross margin of 82.89%, contributing significantly to the company's turnaround [4]. Group 3: Market Competition and Challenges - Despite the turnaround, *ST Suwu faces significant cash flow pressure, with cash reserves dropping from 1.152 billion yuan in 2024 to 168 million yuan in Q1 2025, against short-term borrowings of 1.304 billion yuan [5]. - The medical aesthetics market is highly competitive, with eight similar products already approved in China, posing a risk to *ST Suwu's market position [5]. - The exclusive sales rights for the "Tian Yan Needle" will last until 2032, but competition from other companies, including a major player acquiring the parent company of the product, could impact future sales [5][6].

Core Viewpoint - The performance of Jinbo Biological, the first domestic "recombinant collagen" company, is experiencing significant growth, with revenue and net profit for 2024 projected to be 1.443 billion yuan and 732 million yuan, respectively, reflecting year-on-year increases of 84.92% and 144.27% [1][3]. Financial Performance - In Q1 2025, Jinbo Biological's revenue and net profit are expected to reach 366 million yuan and 169 million yuan, respectively, with both showing over 60% year-on-year growth [1]. - The product "Wei Yimei," which is based on recombinant type III human collagen, generated revenue of 1.128 billion yuan in 2024, marking a year-on-year growth of 99.69% [3][4]. Pricing and Market Pressure - The factory price of Wei Yimei has shown a slight decline, with a 2024 price of 910 yuan per unit, down nearly 7% year-on-year [8]. - The terminal price of Wei Yimei is also decreasing, with a price drop of over 10% observed on platforms like Meituan [10]. Competitive Landscape - Competitors such as Juzi Biological and Chuangjian Medical are making progress in the market, having submitted applications for the registration of similar products, although their approval processes have faced delays [11][12]. - Jinbo Biological's competitive edge lies in its exclusive medical device certification for its injection products, which has driven significant sales growth [3][4]. Product Development - Jinbo Biological is expanding its product range, with the recent approval of a new injectable recombinant collagen gel, which is expected to enhance its market position [14][18]. - The gel is designed for facial volume correction and does not rely on cross-linking agents, potentially increasing safety but limiting the duration of its effects [15][16]. Market Expectations - The strong growth in performance and the upcoming gel product have raised market expectations for Jinbo Biological, with its stock price increasing by nearly 40% since the end of March [19]. - The skincare line related to recombinant collagen also showed significant growth, with revenue of 142 million yuan in 2024, up over 80% year-on-year, although its overall contribution remains limited [21][22].